Loading quotes...

Forecast

The analysts' average price target is €51.72 (+40.16%). The median is €56.57 (+53.31%).

Buy	9
Hold	5
Sell	0

News Go to news feed

Supernus on growth path after patent losses thanks to Qelbree, ONAPGO and ZURZUVAE

Supernus has overcome the revenue decline caused by patent losses for Oxtellar XR and Trokendi XR and is relying on internal research as well as acquisitions to refresh its portfolio. In the second quarter of 2025 revenue rose 32% and four growth products together grew by more than 50%; the 2025 full‑year guidance was raised to $860–890 million. Drivers are Qelbree (strong prescription growth), ONAPGO (supply issues resolved) and ZURZUVAE; the pipeline is focused on SPN‑820 and SPN‑817 as potential future growth sources. » More on de.investing.com
Supernus presents merger plans with Indivior and growth targets at Cantor conference

At the Cantor Fitzgerald Global Healthcare Conference, Supernus outlined revenue and merger plans, highlighted an increased 2024 revenue target of $860–890 million and adjusted EBITDA of $150–180 million, and a 2027 revenue goal of $1 billion. CEO Jack Khattar emphasized the planned merger with Indivior, saying it should strengthen diversification and financial flexibility, but continued to give cautious guidance. Commercial drivers include Qelbree (strong prescription growth), ONAPGO’s recovery after supply constraints, and Zurzuvae’s launch above expectations; SPN-820 remains the most advanced pipeline program with an ongoing placebo-controlled study. » More on de.investing.com
Supernus Pharmaceuticals hits 52-week low at $42.39

Shares of Supernus Pharmaceuticals fell to a 52-week low of $42.39, down about 5% year-to-date and roughly 19% over the past six months. In the second quarter the company reported revenue of $219.1 million but missed adjusted earnings, posting a loss of $1.01 per share versus an expected $0.43. Supernus announced a planned merger with Indivior, which would produce pro‑forma revenue of about $2.2 billion and adjusted EBITDA of $888 million. Analysts have price targets between $55 and $67, implying upside of up to 44%. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Supernus Pharmaceuticals has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Supernus Pharmaceuticals had revenue of €191.94m and net profit of -€51.15m

(EUR)	June 2026	YoY
Revenue	191.94m	36.74%
Gross profit	162.44m	28.82%
Net profit	-51.15m	367.94%
EBITDA	-25.92m	180.35%

Fundamentals

Metric	Value
Market capitalization	€2.13bn
Number of shares	58.22m
52-week high/low	€53.59 - €33.71
Dividends	No
Beta	0.55
P/E ratio	-21.22
PEG ratio	0.20
P/B ratio	2.30
P/S ratio	2.86

Company profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Name	Supernus Pharmaceuticals
CEO	Jack A. Khattar
Headquarters	Rockville, md USA
Website	supernus.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	02/01/2008
Employees	778